37
Participants
Start Date
February 14, 2022
Primary Completion Date
May 31, 2022
Study Completion Date
May 31, 2022
Pyronaridine Tetraphosphate
A total of 24 participants will be dosed with pyronaridine tetraphosphate, sixteen participants will be additionally be dosed with piperaquine tetraphosphate, eight patients will additionally be dosed with placebo.
Piperaquine tetraphosphate
A total of 24 participants will be dosed with piperaquine tetraphosphate, sixteen participants will be additionally be dosed with pyronaridine tetraphosphate, eight patients will additionally be dosed with placebo.
Placebo
Placebo tablets will be administered in combination with pyronaridine tetraphosphate (8 patients), OR, in combination with piperaquine tetraphosphate (8 patients), OR, only matched placebo tablets will be administered (8 patients)
Richmond Pharmacology Ltd, London
Collaborators (1)
Richmond Pharmacology Limited
INDUSTRY
PharmaKinetic Ltd
INDUSTRY
Medicines for Malaria Venture
OTHER